Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNMA1 | Q12791 | 1/20 | 0.66 |
| ▸ | KCNMB4 | Q86W47 | 1/20 | 0.66 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.65 |
| ▸ | RXFP4 | Q8TDU9 | 5/20 | 0.61 |
| ▸ | RXFP3 | Q9NSD7 | 5/20 | 0.61 |
| ▸ | TSLP | Q969D9 | 3/20 | 0.59 |
| ▸ | GLP1R | P43220 | 2/20 | 0.57 |
| ▸ | GCGR | P47871 | 2/20 | 0.57 |
| ▸ | F11 | P03951 | 1/20 | 0.57 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.56 |
| ▸ | NPR1 | P16066 | 1/20 | 0.55 |
| ▸ | NPR3 | P17342 | 1/20 | 0.55 |
| ▸ | BECN1 | Q14457 | 3/20 | 0.55 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.55 |
| ▸ | BAD | Q92934 | 1/20 | 0.55 |
| ▸ | PRLHR | P49683 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29424808 | 0.85 | RXFP1 (0.67) | KCNMA1KCNMB4RXFP1RXFP4RXFP3 | |
| SCHEMBL29438822 | 0.81 | KCNMA1 (0.66) | KCNMA1KCNMB4RXFP1RXFP4RXFP3 | |
| SCHEMBL29369035 | 0.80 | KCNMA1 (0.67) | KCNMA1KCNMB4RXFP1RXFP4RXFP3 | |
| SCHEMBL29356518 | 0.80 | KCNMA1 (0.59) | KCNMA1KCNMB4RXFP1RXFP4RXFP3 | |
| SCHEMBL29353028 | 0.78 | F12 (0.57) | RXFP1TSLPF11PRLHR | |
| SCHEMBL29462295 | 0.78 | MC4R (0.70) | KCNMA1KCNMB4RXFP1F11 | |
| SCHEMBL29607029 | 0.77 | CSNK2A2 (0.67) | KCNMA1KCNMB4RXFP1RXFP4RXFP3 | |
| SCHEMBL29471038 | 0.77 | SSTR2 (0.60) | KCNMA1KCNMB4RXFP1RXFP4RXFP3 | |
| SCHEMBL29375073 | 0.76 | NPR1 (0.59) | KCNMA1KCNMB4RXFP1RXFP4RXFP3 | |
| SCHEMBL14190135 | 0.76 | PRLHR (0.58) | KCNMA1KCNMB4RXFP4RXFP3TSLP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 64 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250213627-A1 | RECOMBINANT MICROORGANISM-BASED METHODS AND COMPOSITIONS FOR TREATMENT OF DISEASE | BAYLOR COLLEGE OF MEDICINE (US) | 2025-07-03 | — | — | US | claimed |
| EP-4367217-A1 | RECOMBINANT MICROORGANISM-BASED METHODS AND COMPOSITIONS FOR TREATMENT OF DISEASE | Baylor College of Medicine (US) | 2024-05-15 | — | — | EP | claimed |
| US-20230042176-A1 | METHOD FOR TREATING ANGELMAN SYNDROME AND RELATED DISORDERS | NAT UNIV SINGAPORE (SG) | 2023-02-09 | — | — | US | claimed |
| WO-2023283646-A1 | RECOMBINANT MICROORGANISM-BASED METHODS AND COMPOSITIONS FOR TREATMENT OF DISEASE | BAYLOR COLLEGE OF MEDICINE (US) | 2023-01-12 | — | — | WO | claimed |
| EP-4076471-A1 | METHOD FOR TREATING ANGELMAN SYNDROME AND RELATED DISORDERS | National University of Singapore (SG) | 2022-10-26 | — | — | EP | claimed |
| US-12606937-B2 | Humanized antibodies with ultralong complementary determining regions | TAURUS BIOSCIENCES, LLC (US) | 2026-04-21 | — | — | US | disclosed |
| US-20260008748-A1 | COMPOUNDS WITH BIGUANIDYL RADICAL AND USES THEREOF | INST CURIE (FR) | 2026-01-08 | — | — | US | disclosed |
| US-20250376494-A1 | INSECTICIDAL CYSTEINE RICH PEPTIDE EXPRESSION IN PLANTS | Vestaron Corporation (US) | 2025-12-11 | — | — | US | disclosed |
| WO-2025227157-A1 | MODIFIED CELLS AND USES THEREOF | UNIVERSITY OF MIAMI (US) | 2025-10-30 | — | — | WO | disclosed |
| US-12433949-B2 | Sustained release delivery systems comprising traceless linkers | NOVARTIS AG (CH) | 2025-10-07 | — | — | US | disclosed |
| US-20250292865-A1 | DETERMINING BIOLOGICAL PARAMETERS OF A CELL | THE UNIVERSITY OF BATH (GB) | 2025-09-18 | — | — | US | disclosed |
| US-12415781-B2 | Compounds with biguanidyl radical and uses thereof | INSTITUT CURIE (FR) | 2025-09-16 | — | — | US | disclosed |
| US-20220193096-A1 | INHIBITORS OF NCCA-ATP CHANNELS FOR THERAPY | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS | 2022-06-23 | — | — | US | disclosed |
| US-20220143129-A1 | METHODS AND COMPOSITIONS FOR TREATING MUCOSAL TISSUE DISORDERS | UNIV NORTH CAROLINA CHAPEL HILL (US) | 2022-05-12 | — | — | US | disclosed |
| US-20220133849-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF SMOOTH MUSCLE DYSFUNCTION | UROVANT SCIENCES GMBH (CH) | 2022-05-05 | — | — | US | disclosed |
| US-20220127337-A1 | Anti-Viroporin Antibodies and Methods of Treating COVID-19 | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED | 2022-04-28 | — | — | US | disclosed |
| US-11278595-B2 | Peptides comprising non-natural amino acids and methods of making and using the same | LONGEVITY BIOTECH, INC. (US) | 2022-03-22 | — | — | US | disclosed |
| US-20220054499-A1 | SMALL MOLECULES FOR MOUSE SATELLITE CELL PROLIFERATION | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2022-02-24 | — | — | US | disclosed |
| US-11246858-B2 | Immunoresponsive methods of treating tumors | INSTITUT PASTEUR DE MONTEVIDEO (UY) | 2022-02-15 | — | — | US | disclosed |
| US-11246879-B2 | Methods, agents, and devices for local neuromodulation of autonomic nerves | Tulai Therapeutics, Inc. (US) | 2022-02-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12606937-B2 | Humanized antibodies with ultralong complementary determining regions | IGLV6-57, FCGR3B, VSIR | KCNMA1 2682/4885KCNMB4 742/4885RXFP1 1234/4885 |
| US-12415781-B2 | Compounds with biguanidyl radical and uses thereof | OGG1, MGMT, DPYD | KCNMA1 2159/4885KCNMB4 1839/4885RXFP1 2761/4885 |
| US-20220054499-A1 | SMALL MOLECULES FOR MOUSE SATELLITE CELL PROLIFERATION | MKI67, MYLK2, MYH2 | KCNMA1 3102/4885KCNMB4 3173/4885RXFP1 1794/4885 |
| US-20230042176-A1 | METHOD FOR TREATING ANGELMAN SYNDROME AND RELATED DISORDERS | UBE3A, UBE3C, UBQLN1 | KCNMA1 20/4885KCNMB4 82/4885RXFP1 2027/4885 |
| US-20260008748-A1 | COMPOUNDS WITH BIGUANIDYL RADICAL AND USES THEREOF | CBR3, ROS1, CBR1 | KCNMA1 1156/4885KCNMB4 611/4885RXFP1 3033/4885 |
| US-12433949-B2 | Sustained release delivery systems comprising traceless linkers | ABCB11, ABCB1, GHRHR | KCNMA1 4420/4885KCNMB4 3598/4885RXFP1 714/4885 |
| US-11278595-B2 | Peptides comprising non-natural amino acids and methods of making and using the same | APLNR, SCTR, GIPR | KCNMA1 3003/4885KCNMB4 3689/4885RXFP1 98/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.